Founder, CEO, and president of EyeBio
Appears in 1 story
Leading EyeBio as a wholly-owned Merck subsidiary
Merck said Thursday its experimental eye drug remigromig hit the primary endpoint in a 984-patient trial for diabetic macular edema. Both tested doses matched ranibizumab, the long-standing standard, on visual acuity at 52 weeks.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
